3 results about "Phosphorylethanolamine" patented technology

The application relates to a sample pretreatment method for pyrite element analysis. First, a pretreatment agent is prepared: carboxymethyl chitosan is activated on the surface through NHS / EDC, and then reacts with phosphoethanolamine to obtain the pretreatment agent; secondly, a pyrite sample is crushed into particles, and is fully ground into powder together with NaOH, NaNO3 and the pretreatment agent; then, the temperature is increased to 180-250 DEG C and then to 350-450 DEG C for heat preservation; the sintered solid is transferred into a beaker, hot nitric acid solution is added, ultrasonic is used to dissolve the solid, and after cooling, filtration is carried out into a volumetric flask, and dilute nitric acid is used for constant volume to obtain a sample to be tested. The treatment method avoids the use of a large amount of concentrated acid and perchloric acid, the reagent consumption is small, and the method is environment-friendly; the treated sample is determined by an ICP-MS instrument and the like, and the recovery rate can be ensured to be above 95%; compared with a standard value, the RSD value is not more than 5%, and the accuracy is good.

A use of gut microbiota or a metabolite thereof and / or an antibody or a derivative thereof in preparation of immunotherapeutic drugs for colorectal cancer. The gut microbiota comprises at least one of Alistipes shahii, Butyricimonas virosa, Desulfovibrio piger, Actinomyces humiferus, Odoribacter splanchnicus, Faecalibacterium prausnitzii, Phocaeicola plebeius, Eubacterium rectale, Oscillospiraceae bacterium, and Alistipes onderdonkii. The metabolite of the gut microbiota comprises at least one of O-phosphorylethanolamine, 5,6-dihydroxyindole-2-carboxylic acid, phosphatidylcholine (O-16:0_20:4), and 4-acetamidobutyric acid. The antibody comprises an IL-17A signaling pathway monoclonal antibody and / or a colorectal cancer-targeted monoclonal antibody.

A lipid nanoparticle and a method of delivering a nucleic acid encapsulated in the lipid nanoparticle to a cell or a subject. The lipid nanoparticle may contain 55-65 mol% of a cationic lipid to the total lipid amount of the lipid nanoparticle; 30-40 mol% of a sterol to the total lipid amount of the lipid nanoparticle; 1-3 mol% of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) to the total lipid amount of the lipid nanoparticle; and 1-5 mol% of 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol (DMG-PEG) to the total lipid amount of the lipid nanoparticle. The lipid nanoparticle may also contain 55-65 mol% of a cationic lipid to a total lipid amount of the lipid nanoparticle; 30-40 mol% of a sterol to the total lipid amount of the lipid nanoparticle; 4-6 mol% of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) to the total lipid amount of the lipid nanoparticle; and 1-5 mol% of 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol (DMG-PEG) to the total lipid amount of the lipid nanoparticle.